Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4475-4479

  Berruti, Alfredo ^a   Mosca, Alessandra ^a   Bitossi, Raffaella ^a   Gorzegno, Gabriella ^a   Guercio, Stefano ^a   Poggio, Massimiliano ^a   Tampellini, Marco ^a   Porpiglia, Francesco ^a   Ostellino, Oliviero ^b   Scarpa, Roberto Mario ^a   Dogliotti, Luigi ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b Oncologia Medica   (Italy)

^c SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Epirubicin; Hormone refractory; Prostate cancer

Indexed keywords

EPIRUBICIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG TOLERABILITY; FEASIBILITY STUDY; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROSTATE CANCER; RHEUMATIC DISEASE; THROMBOCYTOPENIA;

ADENOCARCINOMA; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEASIBILITY STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 28444497698     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. De Angelis R, Capocaccia R and Verdecchia A: Estimative relative survival of Italian cancer patients from sparse cancer registries data. Tumori 83: 33-38, 1997.
2. Goodin S, Rao KV and Di Paola RS: State-of-the art treatment of metastatic hormone-refractory prostate cancer patients. Oncologist 7: 360-370, 2002.
3. Culine S and Droz JP: Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? Ann Oncol 11: 1523-1530, 2002.
4. Elomaa I, Kellokumpu-Lehtinen P, Rannikko S and Alfthan O: Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose treatments. Eur Urol 79: 12-15, 1991.
5. Brausi M, Jones WG, Fossa SD, de Mulder PH, Droz JP, Lentz MA, van Glabbeke M and Pawinski A: High dose Epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC genitourinary group. Eur J Cancer 10: 1622-1626, 1995.
6. Veronesi A, Re GL, Foladore S, Merlo A, Giuliotto N, Talamini R and Monfardini S: Multidrug chemotherapy in the treatment of non-elderly patients with hormone-refractory prostatic carcinoma. A phase II study. North-Eastern Italian Oncology Group (GOCCNE). Eur Urol 29: 434-438, 1996.
7. Chao D, von Schlippe M and Harland SJ: A phase II study of continuous infusion 5-fluorouracil (5-FU) with and cisplatin in metastatic, hormone-resistant prostate cancer: an active regimen. Eur J Cancer 33: 1230-1233, 1997.
8. Burk K: Weekly chemotherapeutic regimen in metastatic prostate cancer patients. Prog Clin Biol Res 350: 187-200, 1990.
9. Neri B, Barbagli G, Bellesi P, Di Loro R, Lombardi V, Lombardo C, Magrini T, Mottola A, Nicita G, Palminteri E, Ponchietti R, Raugei A and Intini C: Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer. Anticancer Res 17: 3817-3820, 1997.
10. Francini G, Petrioli R, Manganelli A, Cintorino M, Marsili S, Aquino A and Mondillo S: Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 67: 1430-1436, 1993.
11. Anderström C: Experiences with doxo/ and medroxyprogesterone acetate (MPA) in prostatic cancer. Cancer Chemother Pharmacol 35(suppl): S97-S100, 1994.
12. Culine S, Kattan J, Zanetta S, Theodore C, Fizazi K and Droz JP: Evaluation of estramustine phosphate combined with weekly doxotubicin in patients with androgen-independent prostate cancer. Am J Clin Oncol (CCT) 21: 470-474, 1998.
13. van Andel G, Kurth KH, Rietbroek RL and van De Velde-Muusers JA: Quality of life assessment in patients with hormone-resistant prostate cancer treated with Epirubicin or plus medroxyprogesterone acetate - is it feasible? Eur Urol 38: 259-264, 2000.
14. Hernes EH, Fossa SD, Vaage S, Ogreid P, Heilo A and Paus E: Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study. Br J Cancer 76: 93-99, 1997.
15. Pummer K, Lehnert M, Stettner H and Hubmer G: Randomized comparison of total androgen blockade alone versus combined with weekly in advanced prostate cancer. Eur Urol 32(Suppl 3): 81-85, 1997.
16. Nicolella D, Grimaldi G, Colantuoni G, Belli M, Frasci G, Perchard J and Comella P: Weekly low dose Epirubicin in elderly cancer patients. Tumori 82: 369-371, 1996.
17. Falcone A, Antonuzzo A, Danesi R, Allegrini G, Monica L, Pfanner E, Masi G, Ricci S, Del Tacca M and Conte P: Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 56: 470-476, 1999.
18. de Vries EG, Greidanus J, Mulder NH, Nieweg MB, Postmus PE, Schipper DL, Sleijfer DT, Uges DR and Willemse PH: A phase I and pharmacokinetic study with 21-day continuous infusion of Epirubicin. J Clin Oncol 5(9): 1445-1451, 1987.
19. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
20. Coleman RE: Evaluation of bone disease in breast cancer. Breast 3: 73-78, 1993.
21. Morris MJ, Santamauro J, Shia J, Schwartz L, Vander Els N, Kelly K and Scher H: Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. Urology 60: 1111, 2002.
22. Hrafnkelsson J, Nilsson K and Soderberg M: Tolerance of radiotherapy combined with adjuvant chemotherapy in breast cancer. Acta Oncol 26: 269-272, 1987.
23. Gochuico BR: Potential pathogenesis and clinical aspects of pulmonary fibrosis associated with rheumatoid arthritis. Am J Med Sci 321: 83-88, 2001.
24. van der Veen MJ, Dekker JJ, Dinant HJ, van Soesbergen RM and Bijlsma JW: Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol 22: 1766-1768, 1995.
25. Dobbs RM, Barber JA, Weigel JM and Bergin JE: Clotting predisposition in carcinoma of the prostate. J Urol 123: 706-709, 1980.
26. Masci G, Magagnoli M, Zucali PA, Castagna L, Carnaghi C, Sarina B, Pedicini V, Fallini M and Santoro A: Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 21: 736-739, 2003.
27. Danesi R, Fogli S, Gennari A, Conte P and Del Tacca M: Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41: 431-444, 2002.